{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:00:48Z","timestamp":1781614848521,"version":"3.54.5"},"reference-count":53,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"the National Health"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.2217\/fon.14.14","type":"journal-article","created":{"date-parts":[[2014,1,28]],"date-time":"2014-01-28T19:49:45Z","timestamp":1390938585000},"page":"789-802","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":40,"title":["Anamorelin Hydrochloride in the Treatment of Cancer Anorexia-Cachexia Syndrome"],"prefix":"10.1080","volume":"10","author":[{"given":"David C","family":"Currow","sequence":"first","affiliation":[{"name":"Discipline of Palliative & Supportive Services,Flinders University, GPO Box 2100, Adelaide, SA 5001, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy P","family":"Abernethy","sequence":"additional","affiliation":[{"name":"Center for Learning Health Care,Duke Clinical Research Institute, DUMC 3436, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,5,5]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13539-010-0002-6"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70218-7"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-010-0127-z"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyt075"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-061509-131248"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2012.209"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601781"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0148607109341804"},{"issue":"11","key":"e_1_3_2_3_9_1","doi-asserted-by":"crossref","first-page":"636","DOI":"10.20452\/pamw.510","article-title":"Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome \u2013 a systematic review and meta-analysis","volume":"118","author":"Le\u015bniak W","year":"2008","unstructured":"Le\u015bniak W , BalaM, JaeschkeR, KrzakowskiM. Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome \u2013 a systematic review and meta-analysis. Pol. Arch. Med. Wewn.118(11), 636\u2013644 (2008).","journal-title":"Pol. Arch. Med. Wewn."},{"key":"e_1_3_2_3_10_1","first-page":"CD004310","article-title":"Megestrol acetate for treatment of anorexia-cachexia syndrome.","volume":"3","author":"Ruiz Garcia V","year":"2013","unstructured":"Ruiz Garcia V , L\u00f3pez-BrizE, Carbonell SanchisR, Gonzalvez PeralesJL, Bort-MartiS. Megestrol acetate for treatment of anorexia-cachexia syndrome.Cochrane Database Syst. Rev.3, CD004310 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_3_11_1","first-page":"CD008664","article-title":"Thalidomide for managing cancer cachexia","volume":"4","author":"Reid J","year":"2012","unstructured":"Reid J , MillsM, CantwellM, CardwellCR, MurrayLJ, DonnellyM. Thalidomide for managing cancer cachexia. Cochrane Database Syst. Rev.4, CD008664 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2008.06.005"},{"key":"e_1_3_2_3_13_1","first-page":"CD004597","article-title":"Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia","volume":"1","author":"Dewey A","year":"2007","unstructured":"Dewey A , BaughanC, DeanT, HigginsB, JohnsonI. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst. Rev.1, CD004597 (2007).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.e18059"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.24990"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2010.02.012"},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70055-X"},{"key":"e_1_3_2_3_18_1","first-page":"LBA21","article-title":"Results from two Phase 3 randomized trials of enobosarm, selective androgen receptor modulator (SARM), for the prevention and treatment of muscle wasting in NSCLC.","volume":"49","author":"Crawford J","year":"2013","unstructured":"Crawford J , DaltonJT, HancockML et al. Results from two Phase 3 randomized trials of enobosarm, selective androgen receptor modulator (SARM), for the prevention and treatment of muscle wasting in NSCLC. Eur. J. Cancer 49(Suppl. 2), LBA21 (2013).","journal-title":"Eur. J. Cancer"},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S39771"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13539-011-0046-2"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-012-1256-4"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2009.10.008"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.01.017"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0800708105"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7254.2006.00319.x"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011749"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/45230"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/35051587"},{"issue":"6","key":"e_1_3_2_3_29_1","first-page":"1393","article-title":"Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoid-related cachexia","volume":"28","author":"Wang W","year":"2006","unstructured":"Wang W , AnderssonM, Iresj\u00f6BM, L\u00f6nnrothC, LundholmK. Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoid-related cachexia. Int. J. Oncol.28(6), 1393\u20131400 (2006).","journal-title":"Int. J. Oncol."},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-0016"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031768"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-7534(20)33024-6"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M205366200"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1800-0"},{"key":"e_1_3_2_3_35_1","first-page":"583","article-title":"Pharmacokinetic (PK) profile of RC-1291, a novel oral ghrelin mimetic for the treatment of cancer anorexia\/cachexia","volume":"14","author":"Blum R","year":"2006","unstructured":"Blum R , PolvinoW. Pharmacokinetic (PK) profile of RC-1291, a novel oral ghrelin mimetic for the treatment of cancer anorexia\/cachexia. Support. Care Cancer14, 583\u2013687 (2006) (Abstract 03-010).","journal-title":"Support. Care Cancer"},{"key":"e_1_3_2_3_36_1","first-page":"583","article-title":"Biologic activity of RC-1291, a novel oral ghrelin mimetic for cancer anorexia\/cachexia: results from a Phase I randomized, double-blind, placebo-controlled trial in healthy volunteers","volume":"14","author":"Kumor K","year":"2006","unstructured":"Kumor K , PolvinoW. Biologic activity of RC-1291, a novel oral ghrelin mimetic for cancer anorexia\/cachexia: results from a Phase I randomized, double-blind, placebo-controlled trial in healthy volunteers. Support. Care Cancer14, 583\u2013687 (2006) (Abstract 03-009).","journal-title":"Support. Care Cancer"},{"key":"e_1_3_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-594"},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2008.12.003"},{"key":"e_1_3_2_3_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.25.18_suppl.9133"},{"key":"e_1_3_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-7534(20)34135-1"},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1500-1"},{"key":"e_1_3_2_3_42_1","first-page":"1316","article-title":"Anamorelin\u2018s effect on bone mass: beyond the expected outcomes in non-small cell lung (NSCLC) cancer cachexia.","volume":"49","author":"Lu M","year":"2013","unstructured":"Lu M , ZabbatinoSM, GarciaJM, Manning DuusE, FriendJ. Anamorelin\u2018s effect on bone mass: beyond the expected outcomes in non-small cell lung (NSCLC) cancer cachexia.Eur. J. Cancer49(Suppl. 2), 1316 (2013).","journal-title":"Eur. J. Cancer"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.tps9649"},{"key":"e_1_3_2_3_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/61.1.72"},{"key":"e_1_3_2_4_2_1","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Palliative Care 2013. www.nccn.org\/professionals\/physician_gls\/pdf\/palliative.pdf (Accessed 14November2013)."},{"key":"e_1_3_2_4_3_1","unstructured":"European Palliative Care Research Collaborative. European Clinical Guidelines: Clinical practice guidelines on cancer cachexia in advanced cancer patients with a focus on refractory cachexia 2010. www.epcrc.org\/guidelines.php?p=cachexia (Accessed 14November2013)."},{"key":"e_1_3_2_4_4_1","unstructured":"ClinicalTrials.gov. Pilot clinical trial of repeated doses of macimorelin to assess safety and efficacy in patients with cancer cachexia. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01614990 (Accessed 14November2013)."},{"key":"e_1_3_2_4_5_1","unstructured":"Ghrelin (Human). ChemicalBook.com. www.chemicalbook.com\/ChemicalProductProperty_EN_CB1240638.htm"},{"key":"e_1_3_2_4_6_1","unstructured":"Temel J Bondarde S Jain M Allen S Mann W. Efficacy and safety of anamorelin HCl in NSCLC patients: results from a randomized double-blind placebo-controlled multicenter Phase II study. European Cancer Congress. Amsterdam The Netherlands 1308 (2013). www.poster-submission.com\/board (Accessed 14November2013)."},{"key":"e_1_3_2_4_7_1","doi-asserted-by":"crossref","unstructured":"Garcia JM Yan Y Duus E Friend J. Anamorelin\u2018s effects on appendicular lean body mass in cancer patients with cachexia: results from a Phase II randomized double blind multicenter study. European Society for Medical Oncology Congress. Vienna Austria 1588 (2012). www.poster-submission.com\/search\/select\/33 (Accessed 14November2013).","DOI":"10.1016\/S0923-7534(20)34135-1"},{"key":"e_1_3_2_4_8_1","unstructured":"ClinicalTrials.gov. Safety and efficacy of anamorelin HCl in patients with non-small cell lung cancer-cachexia (ROMANA 1). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01387269 (Accessed 14November2013)."},{"key":"e_1_3_2_4_9_1","unstructured":"ClinicalTrials.gov. Safety and efficacy of anamorelin HCl in patients with non-small cell lung cancer-cachexia (ROMANA 2). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01387282 (Accessed 14November2013)."},{"key":"e_1_3_2_4_10_1","unstructured":"ClinicalTrials.gov. Anamorelin HCl in the treatment of non-small cell lung cancer-cachexia (NSCLC-C): an extension study (ROMANA 3). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01395914 (Accessed 14November2013)."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.14.14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T18:03:03Z","timestamp":1746122583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.14.14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.2217\/fon.14.14"],"URL":"https:\/\/doi.org\/10.2217\/fon.14.14","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-05-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}